Genes, chromosomes, and rhabdomyosarcoma

Genes Chromosomes and Cancer

Volumn 26, Issue 4, 1999, Pages 275-285

  Anderson, John ^a   Gordon, Anthony ^b   Pritchard Jones, Kathy ^b   Shipley, Janet ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR;

CARCINOGENESIS; CHROMOSOME ABERRATION; FUSION GENE; GENE AMPLIFICATION; GENE TRANSLOCATION; HUMAN; MUSCLE DEVELOPMENT; PRIORITY JOURNAL; REVIEW; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA;

ANIMALS; CHROMOSOME ABERRATIONS; HUMANS; RHABDOMYOSARCOMA;

EID: 0032732984     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2264(199912)26:4<275::AID-GCC1>3.0.CO;2-3     Document Type: Review

References (109)

1. Anderson J, Renshaw J, McManus A, Carter R, Mitchell C, Adams S, Pritchard-Jones K. 1997. Amplification of the t(2; 13) and t(1; 13) translocations of alveolar rhabdomyosarcoma in small formalin-fixed biopsies using a modified reverse transcriptase polymerase chain reaction. Am J Pathol 150:477-482.
2. Asmar L, Gehan EA, Newton WA, Webber BL, Marsden HB, van Unnik AJ, Hamoudi AB, Shimada H, Tsokos M, Harms D, Ninfo V, Schmidt D, Cavazzana A, Gonzales-Crussi F, Parham DM, Reiman HM, Beltangedy MS, Sachs N, Triche TJ, Maurer HM. 1994. Agreement among and within groups of pathologists in the classification of rhabdomyosarcoma and related childhood sarcomas. Report of an international study of four pathology classifications. Cancer 74:2579-2588.
3. Ayan I, Dogan O, Kebudi R, Bavbek B, Alatli C, Dervisoglu S, Disci R, Demiryont M. 1997. Immunohistochemical detection of p53 protein in rhabdomyosarcoma: association with clinicopathological features and outcome. J Pediatr Hematol Oncol 19:48-53.
4. Barr FG, Nauta LE, Davis RJ, Scafer BW, Nycum LM, Biegel JA. 1996. In vivo amplification of the PAX3-FKHR and PAX7-FKHR fusion genes in alveolar rhabdomyosarcoma. Hum Mol Genet 5:15-21.
5. Bayani J, THorner P, Zielenska M, Pandita A, Beatty B, Squires JA. 1995. Application of a simplified comparative genomic hybridization technique to screen for gene amplification in pediatric solid tumors. Pediatr Pathol Lab Med 15:831-844.
6. Bennicelli JL, Fredericks WJ, Wilson RB, Rauscher FJ III, Barr FG. 1995. Wild-type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains. Oncogene 11:119-130.
7. Bernasconi M, Remppis A, Fredericks WJ, Rauscher FJ III, Schafer BW. 1996. Induction of apoptosis in rhabdomyosarcoma cells through down- regulation of PAX proteins. Proc Natl Acad Sci USA 93:13164-13169.
8. Besnard-Guerin C, Newsham I, Winqvist R, Cavenee WK. 1996. A common region of loss of heterozygosity in Wilms' tumor and embryonal rhabdomyosarcoma distal to the D11S988 locus on chromosome 11p15.5. Hum Genet 97:163-170.
9. Braun T, Rudnicki MA, Arnold HH, Jaenisch R. 1992. Targeted inactivation of the muscle regulatory gene Myf-5 results in abnormal rib development and perinatal death. Cell 71:369-382.
10. Carbone A, Gloghini A, Volpe R. 1992. The value of immunohistochemistry in the diagnosis of soft tissue sarcomas. Ann Oncol 3(suppl 2):S51-S54.
11. Casola S, Pedone PV, Cavazzana AO, Basso G, Luksch R, d'Amore ES, Carli M, Bruni CB, Riccio A. 1997. Expression and parental imprinting of the H19 gene in human rhabdomyosarcoma. Oncogene 14:1503-1510.
12. Chalepakis G, Goulding M, Read A, Strachan T, Gruss P. 1994. Molecular basis of splotch and Waardenburg PAX-3 mutations. Proc Natl Acad Sci USA 91:3685-3689.
13. Clark J, Rocques PJ, Braun T, Bober E, Arnold HH, Fisher C, Fletcher C, Brown K, Gusterson BA, Carter RL, Cooper CS. 1991. Expression of members of the myf gene family in human rhabdomyosarcomas. Br J Cancer 64:1039-1042.
14. Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C, Hammond D, Hays DM, Herrmann J, Heyn R, Morris-Jones P, Lawerence W, Newton W, Ortega J, Raney RB, Ruymann FB, Tefft M, Webber B, Weiner E, Wharam M, Vietti TJ, Maurer HM. 1995. The third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 13:610-630.
15. Crist WM, Garnsey L, Beltangady MS, Gehan E, Ruymann K, Webber B, Hays DM, Wharam M, Maurer HM. 1990. Prognosis in children with rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Studies I and II - Intergroup Rhabdomyosarcoma Commitree. J Clin Oncol 8:443-152.
16. Daston G, Lamar E, Olivier M, Goulding M. 1996. PAX-3 is necessary for migration but not differentiation of limb muscle precursors in the mouse. Development 122:1017-1027.
17. Davis RJ, D'Cruz CM, Lovell MA, Biegel JA, Barr FG. 1994. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res 54:2869-2872.
18. Diller L, Sexsmith E, Gottlieb A, Li FP, Malkin D. 1995. Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J Clin Invest 95:1606-1611.
19. Douglass EC, Rowe ST, Valentine M, Parham DM, Berkow R, Bowman WP, Maurer HM. 1991. Variant translocations of chromosome 13 in alveolar rhabdomyosarcoma. Genes Chromosomes Cancer 3:480-482.
20. Driman D, Thorner PS, Greenberg ML, Chilton-MacNeill S, Squire J. 1994. MYCN gene amplification in rhabdomyosarcoma. Cancer 15:2231-2237.
21. Duprez D, Fournier-Thibault C, Le Douarin N. 1998. Sonic Hedgehog induces proliferation of committed skeletal muscle cells in the chick limb. Development 125:495-505.
22. Elson DA, Bartolomei MS. 1997. A 5′ differentially methylated sequence and the 3′-flanking region are necessary for H19 transgene imprinting. Mol Cell Biol 17:309-317.
23. Epstein JA, Lam P, Jepeal L, Maas RL, Shapiro DN. 1995. PAX3 inhibits myogenic differentiation of cultured myoblast cells. J Biol Chem 270:11719-11722.
24. Epstein JA, Song B, Lakkis M, Wang C. 1998. Tumor-specific PAX3-KKHR transcription factor, but not PAX3, activates the platelet-derived growth factor alpha receptor. Mol Cell Biol 18:4118-4130.
25. Felix CA, Kappel CC, Mitsudomi T, Nau MM, Tsokos M, Crouch GD, Nisen PD, Winick NJ, Helman LJ. 1992. Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res 52:2243-2247.
26. Fisher C. 1990. The value of electronmicroscopy and immunohistochemistry in the diagnosis of soft tissue sarcomas: a study of 200 cases. Histopathology 16:441-454.
27. Fletcher CD. 1995. Immunohistochemistry in diagnosis of soft tissue sarcomas and new techniques in soft tissue tumor pathology. Recent Results Cancer Res 138:17-24.
28. Forus A, Florenes VA, Maclandsmo GM, Meltzer PS, Fodstat O, Myklebost O. 1993. Mapping of amplification units in the q13-14 region of chromosome 12 in human sarcomas: some amlica do not include MDM2. Cell Growth Differ 4:1065-1070.
29. Forus A, Weghuis DO, Smeets D, Fodstad O, Myklebost O, Geurts van Kessel A. 1995. Comparative genomic hybridization analysis of human sarcomas: occurrence of genomic imbalances and identification of a novel major amplicon at 1q21-q22 in soft tissue sarcomas. Genes Chromosomes Cancer 14:8-14.
30. Frascella E, Toffolatti L, Rosolen A. 1998. Normal and rearranged PAX3 expression in human rhabdomyosarcoma. Cancer Genet Cytogenet 102:104-109.
31. Galili N, Davis RJ, Fredericks WJ, Mukhopadhyay S, Rauscher FJd, Emanuel BS, Rovera G, Barr FG. 1993. Fusion of a fork head domain gene to PAX3 in the solid tumor alveolar rhabdomyosarcoma. Nat Genet 5:230-235.
32. Gil-Benso R, Carda-Batalla C, Navarro-Fos S, Pellin-Perez A, Llombart-Bosch A. 1999. Cytogenetic study of a spindle-cell rhabdomyosarcoma of the partoid gland. Cancer Genet Cytogenet 109:150-153.
33. Goulding M, Sterrer S, Fleming J, Balling R, Nadeau J, Moore KJ, Brown SD, Steel KP, Gruss P. 1993. Analysis of the PAX-3 gene in the mouse mutant splotch. Genomics 17:355-363.
34. Grundy P, Telzerrow P, Moksness J, Breslow NE. 1996. Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis. Med Pediatr Oncol 27:429-433.
35. Hachitanda Y, Toyoshima S, Akazawa K, Tsuneyoshi M. 1998. N-myc gene amplification in rhabdomyosarcoma detected by fluorecence in situ hybridization: its correlation with histologic features. Mod Pathol 11:1222-1227.
36. Hahn H, Wojnowski L, Zimmer AM, Hall J, Miller G, Zimmer A. 1998. Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nat Med 4:619-622.
37. Hao Y, Crenshaw T, Moulton T, Newcomb E, Tycko B. 1993. Tumor-suppressor activity of H19 RNA. Nature 365:764-767.
38. Hasty P, Bradley A, Morris JH, Edmondson DG, Venuti JM, Olson EN, Klein WH. 1993. Muscle deficiency and neonatal death in mice with a targeted mutation in the myogenin gene. Nature 364:501-506.
39. Hatada I, Mukai T. 1995. Genomic imprinting of p57KIP2, a cyclin-dependent kinase inhibitor, in mouse. Nat Genet 11:204-206.
40. Hatada I, Inazawa J, Abe T, Nakayama M, Kaneko Y, Jinno Y, Niikawa N, Ohashi H, Fukushima Y. lida K, Yutani C. Takahashi S, Chiba Y, Ohishi S, Mukai, T. 1996a. Genomic imprinting of human p57KIP2 and its reduced expression in Wilms' tumors. Hum Mol Genet 5:783-788.
41. Hatada I. Ohashi H, Fukushima Y, Kaneko Y, Inoue M, Komoto Y, Okada A, Ohishi S, Nabetani A, Morisaki H. Nakayama M. Niikawa N, Mukai T. 1996b. An imprinted gene p57KIP2 is mutated in Beckwith-Wiedemann syndrome. Nat Genet 14:171-173.
42. Hayashi Y, Inaba T, Hanada R, Yamamoto K. 1987. Translocation 2;8 in a congenital rhabdomyosarcoma. Cancer Genet Cytogenet 30:343-345.
43. Hollowood K. Fletcher CD. 1994. Rhabdomyosarcoma in adults. Semin Diagn Pathol 11:47-57.
44. Hu RJ. Lee MP, Connors TD, Johnson LA, Burn TC, Su K. Landes GM, Feinberg AP. 1997. A 2.5-Mb transcript map of a tumor-suppressing subchromosomal transferable fragment from 11p15.5, and isolation and sequence analysis of three novel genes. Genomics 46:9-17.
45. Iolascon A. Faienza MF, Coppola B, Rosolen A, Basso G, Della Ragione F, Schettini F. 1996. Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B and CDKN2C) in childhood rhabdomyosarcoma. Genes Chromosomes Cancer 15:217-222.
46. Jostes B, Walther C, Gruss P. 1990. The murine paired box gene, PAX7, is expressed specifically during the development of the nervous and muscular system. Mech Dev 33:27-37.
47. Kalebic T, Tsokos M, Helman LJ. 1994. In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2. Cancer Res 54:5531-5534.
48. Keleti J, Quezado MM, Abaza MM, Raffeld M, Tsokos M. 1996. The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein. Am J Pathol 149:143-151.
49. Kelly KM, Womer RB, Sorensen PH, Xiong QB, Barr FG. 1997. Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma. J Clin Oncol 15:1831-1836.
50. Kenet G, Sharon N, Rosner E, Toren A, Neumann Y, Mandel M, Kaplinsky C. Gipish N, Bermann S, Rechavi G. 1998. Chromosomal translocation (1;13) in a case of alveolar rhabdomyosarcoma. J Pediatric Haem Oncol 20:86-87.
51. Khan J, Simon R, Bittner M, Chen Y, Leighten SB, Pohida T, Smith PD, Jiang Y, Gooden GC, Trent J, Meltzer P. 1998. Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res 58:5009-5013.
52. Knudsen ES, Pazzagli C, Born TL, Bertolaet BL, Knudsen KE, Arden KC, Henry RR, Feramisco JR 1998. Elevated cyclins and cyclin-dependant kinase activity in the rhabdomyosarcoma cell line RD. Cancer Res 1:2042-2049.
53. Kullendorff CM, Donner M, Mertens F, Mandahl N. 1998. Chromosomal aberrations in a consecutive series of childhood rhabdomyosarcoma. Med Ped Oncol 30:156-159.
54. Kullendorff CM, Mertens F, Donner M, Wiebe T, Akerman M, Mandahl N. 1999. Cytogenetic aberrations in Ewing sarcoma: are secondary changes associated with clinical outcome? Med Pediatr Oncol 32:79-83.
55. Lam PYP, Sublett JE, Hollenbach AD, Roussel MF. The oncogenic potential of the Pax3-FKHR fusion protein requires the Pax3 homeodomain recognition helix but not the Pax3 paired-box DNA binding domain. Mol Cell Biol 19:594-601.
56. Lee MH, Reynisdottir I, Massague J. 1995. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 9:639-649.
57. Lee MP, Hu RJ, Johnson LA, Feinberg AP. 1997. Human KVLQT1 gene shows tissue-specific imprinting and encompasses Beckwith-Wiedemann syndrome chromosomal rearrangements. Nat Genet 15:181-185.
58. Leighton PA, Ingram RS, Eggenschwiler J, Efstratiadis A, Tilghman SM. 1995. Disruption of imprinting caused by deletion of the H19 gene region in mice. Nature 375:34-39.
59. Ludolph DC, Konieczny SF. 1995. Transcription factor families: muscling in on the myogenic program. Faseb J 9:1595-1604.
60. Mannens M, Alders M, Redeker B, Bliek J, Steenman M, Wiesmeyer C, de Meulemeester M, Ryan A, Kalikin L, Voute T, De Kraker J, Hoovers J, Slater R, Feinberg A, Little P, Westerveld, A. 1996. Positional cloning of genes involved in the Beckwith-Wiedemann syndrome, hemihypertrophy, and associated childhood tumors. Med Pediatr Oncol 27:490-494.
61. Mansouri A, Stoykova A, Torres M, Gruss P. 1996. Dysgenesis of cephalic neural crest derivatives in PAX7-/-mutant mice. Development 122:831-838.
62. McManus AP, O'Reilly MA, Pritchard-Jones K, Gusterson BA, Mitchell CD, Pinkerton CR, Shipley JM. 1996. Interphase fluorescence in situ hybridization detection of t(2;13)(q35;q14) in alveolar rhabdomyosarcoma: a diagnostic tool in minimally invasive biopsies. J Pathol 178:410-414.
63. Meddeb M, Valent A, Danglot G, Nguyen VC, Duverger A, Fouquet F, Terrier-Lancombe MJ, Oberlin O, Bernheim A. 1996. MDM2 amplification in a primary alveolar rhabdomyosarcoma displaying a t(2;13)(q32;q14). Cytogenet Cell Genet 73:325-330.
64. Minniti CP, Maggi M, Helman LJ. 1992. Suramin inhibits the growth of human rhabdomyosarcoma by interrupting the insulin-like growth factor II autocrine growth loop. Cancer Res 52:1830-1835.
65. Minniti CP, Tsokos M, Newton WA Jr, Helman LJ. 1994. Specific expression of insulin-like growth factor-II in rhabdomyosarcoma tumor cells. Am J Clin Pathol 101:198-203.
66. Minniti CP. Luan D, O'Grady C, Rosenfeld RG, Oh Y, Helman LJ. 1995. Insulin-like growth factor II overexpression in myoblasts induces phenotypic changes typical of the malignant phenotype. Cell Growth Differ 6:263-269.
67. Mitelman F. 1998. Catalog of Chromosome Aberrations in Cancer '98. CD-ROM. New York: Wiley-Liss.
68. Montagna M, Menin C, Chieco-Bianchi L, D'Andrea E. 1994. Occasional loss of constitutive heterozygosity at 11p15.5 and imprinting relaxation of the IGFII maternal allele in hepatoblastoma. J Cancer Res Clin Oncol 120:732-736.
69. Moulton T, Chung WY, Yuan L, Hensle T, Waber P, Nisen P, Tycko B. 1996. Genomic imprinting and Wilms' tumor. Med Pediatr Oncol 27:476-483.
70. Mrozek K, Bloomfield C. 1998. Der(16)t(1;16) is a secondary change in at least eighteen different types of human cancer. Genes Chromosomes Cancer 23:78-80.
71. Munsterberg AE, Kitajewski J, Bumcrot DA, McMahon AP, Lassar, AB. 1995. Combinatorial signaling by sonic hedgehog and Wnt family members induces myogenic bHLH gene expression in the somite. Genes Dev 9:2911-2922.
72. Nabeshima Y, Hanaoka K, Hayasaka M, Esumi E, Li S, Nonaka I. 1993. Myogenin gene disruption results in perinatal lethality because of severe muscle defect. Nature 364:532-535.
73. Newton WA Jr, Gehan EA, Webber BL, Marsden HB, van Unnik AJ, Hamoudi AB, Tsokos MG, Shimada H, Harms D, Schmidt D, Ninfo V, Cavazzana AO, Gonzalez-Crussi F, Parham DM, Reiman HM, Asmar L, Beltangedy MS, Sachs NE, Triche TJ, Maurer HM. 1995. Classification of rhabdomyosarcomas and related sarcomas: pathologic aspects and proposal for a new classification - an Intergroup Rhabdomyosarcoma Study. Cancer 76:1073-1085.
74. Nystrom A, Cheetham JE, Engstrom W, Schofield PN. 1992. Molecular analysis of patients with Wiedemann-Beckwith syndrome. II. Paternally derived disomies of chromosome 11. Eur J Pediatr 151:511-514.
75. O'Keefe D, Dao D, Zhao L, Sanderson R, Warburton D, Weiss L, Anyane-Yeboa K, Tycko B. 1997. Coding mutations in p57KIP2 are present in some cases of Beckwith-Wiedemann syndrome but are rare or absent in Wilms tumors. Am J Hum Genet 61:295-303.
76. Pedone PV, Tirabosco R, Cavazzana AO, Ungaro P, Basso G, Luksch R, Carli M, Bruni CB, Frunzio R, Riccio, A. 1994. Mono- and bi-allelic expression of insulin-like growth factor II gene in human muscle tumors. Hum Mol Genet 3:1117-1121.
77. Ping AJ, Reeve AE, Law DJ, Young MR, Boehnke M, Feinberg, AP. 1989. Genetic linkage of Beckwith-Wiedemann syndrome to 11p15. Am J Hum Genet 44:720-723.
78. Polito P, Dal Cin P, Sciot R, Brock P, Van Eyken P, Van der Berghe H. 1999. Embryonal rhabdomyosarcoma with only numerical chromosome changes. Cancer Genet Cytogenet 109:161-165.
79. Qian N, Frank D, O'Keefe D, Dao D, Zhao L, Yuan L, Wang Q, Keating M, Walsh C, Tycko, B. 1997. The IPL gene on chromosome 11p15.5 is imprinted in humans and mice and is similar to TDAG51, implicated in Fas expression and apoptosis. Hum Mol Genet 6:2021-2029.
80. Ripoche MA, Kress C, Poirier F, Dandolo L. 1997. Deletion of the H19 transcription unit reveals the existence of a putative imprinting control element. Genes Dev 11:1596-1604.
81. Rudnicki MA, Braun T, Hinuma S, Jaenisch R. 1992. Inactivation of MYOD in mice leads to up-regulation of the myogenic HLH gene Myf-5 and results in apparently normal muscle development. Cell 71:383-390.
82. Rudnicki MA, Schnegelsberg PN, Stead RH, Braun T, Arnold HH, Jaenisch R. 1993. MYOD or Myf-5 is required for the formation of skeletal muscle. Cell 75:1351-1359.
83. Sabbioni S, Barbanti-Brodano G, Croce CM, Negrini M. 1997. GOK: a gene at 11p15 involved in rhabdomyosarcoma and rhabdoid tumor development. Cancer Res 57:4493-4497.
84. Savasan S, Lorenzana A, Williams J, Mohamed A, Ravindranath Y, Zielenska M, Hamre M, Haas J, Rector F, Sawaf H, Abella E. 1998. Constitutional balanced translocations in alveolar rhabdomyosarcoma. Cancer Genet Cytogenet 105:50-54.
85. Sawyer JR, Crussi FG, Kletzel M. 1994. Pericentric inversion (2)(p15q35) in alveolar rhabdomyosarcoma. Cancer Genet Cytogenet 78:214-218.
86. Scheidler S, Fredericks WJ, Rauscher FJ III, Barr FG, Vogt PK. 1996. The hybrid PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma transforms fibroblasts in culture. Proc Natl Acad Sci USA 93:9805-9809.
87. Schwienbacher C, Sabbioni S, Campi M, Veronese A, Bernardi G, Menegatti A, Hatada I, Mukai T, Ohashi H, Barbanti-Brodano G, Croce CM, Negrini M. 1998. Transcriptional map of 170-kb region at chromosome 11p15.5: identification and mutational analysis of the BWR1A gene reveals the presence of mutations in tumor samples. Proc Natl Acad Sci USA 95:3873-3878.
88. Scrable H, Witte D, Shimada H, Seemayer T, Sheng WW, Soukup S, Koufos A, Houghton P, Lampkin B, Cavenee W. 1989. Molecular differential pathology of rhabdomyosarcoma. Genes Chromosomes Cancer 1:23-35.
89. Shapiro DN, Sublett JE, Li B, Downing JR, Naeve CW. 1993. Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. Cancer Res 53:5108-5112.
90. Shapiro DN, Jones BG, Shapiro LH, Dias P, Houghton PJ. 1994. Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. J Clin Invest 94:1235-1242.
91. Smith L, Liu SJ, Goodrich L, Jacobson D, Degnin C, Bentley N, Carr A, Flaggs G, Keegan K. Hoestra M, Thayer MJ. 1998. Duplication of ATR inhibits MYOD, induces aneuploidy and eliminates radiation-induced G1 arrest. Nat Genet 19:39-46.
92. Steenman MJ, Rainier S, Dobry CJ, Grundy P, Horon IL, Feinberg AP. 1994. Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumor. Nat Genet 7:433-439.
93. Steilen-Gimbel H, Remberger K, Graf N, Steudel WI, Zang KD, Henn W. 1996. A novel site of amplification on chromosome 1p32-33 in a rhabdomyosarcoma revealed by comparative genomic hybridization. Hum Genet 97:87-90.
94. Strong LC, Williams, WR, Tainsky MA. 1992. The Li-Fraumeni syndrome: from clinical epidemiology to molecular genetics. Am J Epidemiol 15:190-199.
95. Tajbakhsh S, Rocancourt D, Cossu G, Buckingham M. 1997. Redefining the genetic hierarchies controlling skeletal myogenesis: PAX-3 and Myf-5 act upstream of MYOD. Cell 89:127-138.
96. Tamir Y, Bengal E. 1998. p53 protein is activated during muscle differentiation and participates with MYOD in the transcription of muscle creatine kinase gene. Oncogene 17:347-356.
97. Taniguchi T, Okamoto K, Reeve AE. 1997. Human p57(KIP2) defines a new imprinted domain on chromosome 11p but is not a tumor suppressor gene in Wilms tumour. Oncogene 13:1201-1206.
98. Tsokos M, Webber BL, Parham DM, Wesley RA, Miser A, Miser JS, Etcubanas E, Kinsella T, Grayson J, Glatstein E et al. 1992. Rhabdomyosarcoma: a new classification scheme related to prognosis. Arch Pathol Lab Med 116:847-855.
99. Urashima M, Teoh G, Akiyama M, Yuza Y, Anderson KC, Maekawa K. 1999. Restoration of p16INK4A protein induces myogenic differentiation in RD rhabdomyosarcoma cells. 79:1032-1036.
100. Visser M, Sijmons C, Bras J, Arceci RJ, Godfried, M, Valentijn LJ, Voute PA, Baas F. 1997. Allelotype of pediatrie rhabdomyosarcoma. Oncogene 15:1309-1314.
101. Wadey RB, Pal, N, Buckle B, Yeomans E, Pritchard J, Cowell JK. 1990. Loss of heterozygosity in Wilms' tumor involves two distinct regions of chromosome 11. Oncogene 5:901-907.
102. Wang W, Kumar P, Epstein J, Helman L, Moore JV, Kumar S. 1998. Insulin-like growth factor II and PAX3-FKHR cooperate in the oncogenesis of rhabdomyosarcoma. Cancer Res 58:4426-4433.
103. Weber-Hall S, Anderson J, McManus A, Abe S, Nojima T, Pinkerton R, Pritchard-Jones K, Shipley J. 1996a. Gains, losses, and amplification of genomic material in rhabdomyosarcoma analyzed by comparative genomic hybridization. Cancer Res 56:3220-3224.
104. Weber-Hall S, McManus A, Anderson J, Nojima T, Abe S, Pritchard-Jones K, Shipley J. 1996b. Novel formation and amplification of thePAX7-FKHR fusion gene in a case of alveolar rhabdomyosarcoma. Genes Chromosomes Cancer 17:7-13.
105. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. 1997. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 16:2985-2995.
106. Werner H, Le Roith D. 1997. The insulin-like growth factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis. Crit Rev Oncog 8:71-92.
107. Yoon JK, Olson EN, Arnold HH, Wold BJ. 1997. Different MRF4 knockout alleles differentially disrupt Myf-5 expression: cis-regulatory interactions at the MRF4/Myf-5 locus. Dev Biol 188:349-362.
108. Zhan S, Shapiro DN, Helman, LJ. 1994. Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J Clin Invest 94:445-448.
109. Zhan S, Helman LJ. 1998. Glimpsing the cause of rhabdomyosarcoma. Nat Med 4:559-560.